Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Urogen Pharma ( (URGN) ) has issued an update.
UroGen Pharma’s shareholders convened at the Annual Meeting to vote on several key proposals. The shareholders elected seven directors, approved an amended compensation policy, and endorsed the 2017 Amended Plan. Additionally, they approved the executive compensation and decided to hold annual advisory votes on this matter. PricewaterhouseCoopers LLP was appointed as the independent auditor until 2026.
The most recent analyst rating on (URGN) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Urogen Pharma stock, see the URGN Stock Forecast page.
Spark’s Take on URGN Stock
According to Spark, TipRanks’ AI Analyst, URGN is a Neutral.
Urogen Pharma’s stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative equity. However, positive technical indicators and recent FDA approval of ZUSDURI provide a bullish outlook. The earnings call and corporate events further support future growth potential, but the valuation remains unattractive due to ongoing losses.
To see Spark’s full report on URGN stock, click here.
More about Urogen Pharma
Average Trading Volume: 2,705,715
Technical Sentiment Signal: Buy
Current Market Cap: $902.2M
For a thorough assessment of URGN stock, go to TipRanks’ Stock Analysis page.